Physician profile
Corby Smithton
NPI 1366437246
$3,292.10
in general payments reported to CMS, 2019-2025
36 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $467 · 2021: $808 · 2022: $408 · 2023: $428 · 2024: $526 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.00 | 2020-2025 | Qulipta, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $324.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Supernus Pharmaceuticals, INC. | $269.69 | 2021-2024 | Qelbree |
| Lilly USA, LLC | $223.98 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $218.06 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $203.97 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.14 | 2019-2024 | Xifaxan |
| Pfizer INC. | $162.12 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.72 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $119.82 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $116.90 | 2022-2023 | Azstarys |
| Novo Nordisk INC | $109.78 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $83.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.69 | 2020-2022 | |
| Dexcom, INC. | $73.03 | 2021-2023 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.82 | 2023-2024 | Prolia, Evenity |
| Exact Sciences Corporation | $50.61 | 2024-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $42.45 | 2021-2022 | |
| Abbott Laboratories | $39.89 | 2021 | |
| Tris Pharma INC | $39.17 | 2024-2025 | Dyanavel Xr |
| Shire North American Group INC | $35.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.88 | 2021 | |
| Sumitomo Pharma America, INC. | $25.31 | 2024 | Gemtesa |
| Bausch Health US, LLC | $24.42 | 2024 | Aplenzin |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.28 | 2022 | |
| Amarin Pharma, INC. | $23.95 | 2019-2020 | |
| Allergan, INC. | $23.67 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.21 | 2025 | |
| Veran Medical Technologies, INC. | $20.99 | 2020 | |
| Organon LLC | $19.28 | 2021 | |
| Geron Corporation | $16.13 | 2025 | Rytelo |
| Idorsia Pharmaceuticals US INC | $15.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.88 | 2020 | |
| Dermira, INC. | $12.49 | 2020 | |
| Almatica Pharma LLC | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corby Smithton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.